Clinical Trial Update: Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis [Phase 4]

View source ↗

Summary

This update reports results from a Phase 4 trial evaluating bone marker changes in postmenopausal osteoporosis treated with teriparatide. The sponsor is Eli Lil…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Forteo (teriparatide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Osteoporosis, Post-Menopausal | Phase 4 | Status: COMPLETED